Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Colorectal Cancer

Gastric Cancers

Liver Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancer

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head and Neck Cancers

Graft-Vs-Host Disease

Leukemia

Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematology

Lung Cancer

Pediatric Cancer

Sarcomas

Melanoma

Skin Cancer

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

Acupuncture Use in BC Predicted by Social Determinants of Health

Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.

Variability Found in PROs, Gene Expression During AML Induction Chemo

Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

Blinatumomab-Linked ICANS Cases Higher Than Previously Reported

News

Latest News

FDA News

Adverse Event Management

Supportive Care

Disparities in Cancer Care

Drug Safety

Radiation Oncology

Survivorship 

Practice Management

Prevention

Contributors

Media

Expert Connections

Morning Rounds

The Vitals

Podcasts

Videos

Between the Lines

Meeting of the Minds

Training Academy

Conferences

Conference Coverage

Conference Listing

Publications

CME/CE

Continuing Education

Resources

Case-Based Digest 

Rx Road Map

Webinars

Cancer Summary Slides

MPN Symptom Management

Events

Subscribe

Partners

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

ODAC Votes Against Talazoparib Combo for Patients With non-HRR mCRPC

Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Durvalumab added to BCG induction and maintenance improved disease-free survival vs BCG alone in high-risk non–muscle-invasive bladder cancer.

Durvalumab Plus BCG Boosts DFS in Non–Muscle-Invasive Bladder Cancer

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

First-line maintenance therapy with lurbinectedin plus atezolizumab has the potential to become a new standard of care in extensive-stage small cell lung cancer.

Lurbinectedin Plus Atezolizumab as Frontline Maintenance Therapy Enhances Survival in ES-SCLC

The phase 3 INAVO120 trial showed that overall survival significantly improved with the addition of inavolisib to palbociclib and fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative, endocrine-resistant advanced breast cancer.

Addition of Inavolisib Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer

About Us

Editorial Board

Contact Us

CancerNetwork.com

CureToday.com

OncLive.com

TargetedOnc.com

Advertise

Privacy

Terms & Conditions

Do Not Sell My Information

Oncology Nursing News

Facebook

LinkedIn

Specialty

Advanced Practice Providers

Clinical

Gynecologic Cancer

Immunotherapy

Nurse Navigation

Quality Improvement

1rem

Singer and songwriter Charlie Lustman has become an inspirational voice for the over 12 million cancer survivors living in the United States

Osteosarcoma Survivor Sings Message of Hope

Half of US states currently have anti-smoking laws; the goal is 100%

Smoking Bans

The release of the data was a requirement of the national health care reform act.

Medicare Data on Healthcare Errors Released

Help kidney cancer patients by being aware of available resources and support services

Resources for People Living with Kidney Cancer

News

Latest Conference Coverage